Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults

ClinicalTrials.gov ID: NCT01165242

Public ClinicalTrials.gov record NCT01165242. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 20, 2026, 7:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years

Study identification

NCT ID
NCT01165242
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
1,013 participants

Conditions and interventions

Interventions

  • Meningococcal vaccine GSK 134612 Biological
  • Menactra® Biological

Biological

Eligibility (public fields only)

Age range
10 Years to 25 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 18, 2010
Primary completion
Feb 24, 2011
Completion
Jul 28, 2011
Last update posted
Jun 25, 2018

2010 – 2011

United States locations

U.S. sites
24
U.S. states
14
U.S. cities
22
Facility City State ZIP Site status
GSK Investigational Site Chandler Arizona 85224
GSK Investigational Site Paramount California 90723
GSK Investigational Site Sacramento California 95816
GSK Investigational Site Sacramento California 95823
GSK Investigational Site Santa Rosa California 95405
GSK Investigational Site Longmont Colorado 80501
GSK Investigational Site Marietta Georgia 30062
GSK Investigational Site Stockbridge Georgia 30281
GSK Investigational Site Woodstock Georgia 30189
GSK Investigational Site Wichita Kansas 67207
GSK Investigational Site Lexington Kentucky 40509
GSK Investigational Site Nicholasville Kentucky 40356
GSK Investigational Site Columbia Maryland 21045
GSK Investigational Site Stevensville Michigan 49127
GSK Investigational Site St Louis Missouri 63141
GSK Investigational Site Syracuse New York 13210
GSK Investigational Site Albany Oregon 97322
GSK Investigational Site Carnegie Pennsylvania 15106
GSK Investigational Site Erie Pennsylvania 16501
GSK Investigational Site Erie Pennsylvania 16505
GSK Investigational Site Hermitage Pennsylvania 16148
GSK Investigational Site Greer South Carolina 29651
GSK Investigational Site Simpsonville South Carolina 29681
GSK Investigational Site Austin Texas 78705

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01165242, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 25, 2018 · Synced Jul 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01165242 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →